Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines

Dec 12, 2016

SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health

Program uses smartphones and tablet computers to improve access to medicines and increase disease surveillance, helping to provide better care for patients

Initiative builds on the success of award-winning SMS for Life and will introduce eLearning for local healthcare workers

Basel, December 12, 2016 - Novartis announced today the launch of an innovative technology-based healthcare program called SMS for Life 2.0 in Kaduna State, Nigeria. The program aims to increase the availability of essential medicines and improve care for patients across the region by using simple, available, and affordable technology. SMS for Life 2.0 is a joint public-private partnership led by Novartis and supported by its partners, the Kaduna State Ministry of Health and Vodacom.

"Novartis is proud to partner with the Kaduna State Ministry of Health to implement the first ever SMS for Life 2.0 program," said Joseph Jimenez, CEO of Novartis. "Companies must join forces with the public sector to co-create innovative solutions to improve access to healthcare around the world. This is the first step in what we hope will be an impactful public health initiative, unleashing the potential of mobile technology and big data to increase the quality of care for underserved patients."

SMS for Life 2.0 builds on the SMS for Life program launched by Novartis in 2009, which used cell phones to manage stock-outs of malaria medicines in more than 10,000 healthcare facilities in sub-Saharan countries. The new and enhanced SMS for Life 2.0 program will now use smartphones and tablet computers to address key operational challenges at peripheral healthcare facilities in Kaduna State. Local healthcare workers will be able to track stock levels of essential antimalarials, vaccines, and HIV, TB and leprosy treatments, and send notifications to district medical officers when stock levels are low. The program will also monitor surveillance parameters of malaria, maternal and infant deaths and seven other diseases, including measles, yellow fever and cholera. In addition, SMS for Life 2.0 will enable training of healthcare workers in local facilities using on-demand eLearning modules.

"We welcome the introduction of SMS for Life 2.0 in primary healthcare facilities, where we often face stockouts of medicines," said Dr. Hadiza S. Balarabe, Executive Secretary of Kaduna State Primary Health Care Development Agency. "With more than six million people, Kaduna is Nigeria's third most populous state. We hope the program will improve healthcare services by expanding access to essential medicines, thus reducing disease prevalence in communities."

Medicines do not always reach the patients who need them, particularly those living in remote areas. Running out of stock is a major hurdle in ensuring access to essential treatments. By increasing stock visibility, health authorities will be able to monitor stock levels of these medicines in real time. Furthermore, disease surveillance data combined with the stock reporting function can improve supply chain management, by allowing authorities to better forecast demand for the treatments. This will help to ensure people get the medicines they need in a timely fashion.

"Vodacom believes that mobile technology is a powerful platform to address healthcare problems in Africa," said Vuyani Jarana, Chief Officer of Vodacom Business. "Our vision in partnering with Kaduna State is to support the development of productive societies which are healthy, well-educated and economically active. The SMS for Life 2.0 initiative will contribute towards better quality and more accessible healthcare services which will in turn contribute to an increase in life expectancy in Nigeria."

In addition to the launch in Nigeria, Novartis and its non-profit partner Right to Care, have signed a memorandum of understanding with the Zambian Ministry of Health to deploy SMS for Life 2.0 in up to 2,000 health facilities across the country. The program, which will include stock reporting, disease surveillance and eLearning, will be supported by Vodacom and is expected to launch in Q2 2017.

About SMS for Life 2.0SMS for Life is a Roll Back Malaria Partnership initiative, led by Novartis, with the purpose of developing and helping countries implement new innovative solutions to the long-standing problem of medicine stock-outs at the remote health facility level in order to significantly improve patient access to healthcare commodities in developing countries.

The program was launched in 2009 by the Novartis Malaria Initiative to manage stock-outs of malaria medicines in sub-Saharan countries. A new enhanced version of this award-winning program, called SMS for Life 2.0, now uses smartphones and tablet computers.

The program allows public healthcare facilities to monitor stock levels of essential medicines such as antimalarials, HIV treatments, and vaccines. Further, it can and will be extended to treatments against noncommunicable diseases. The system sends notifications to district medical officers responsible for treatment availability when stock levels are low, helping to avoid stock-outs. Tablet computers also allow for disease monitoring by supporting data collection of basic disease parameters in line with a country's needs. They can also be used to deliver high-quality training to healthcare workers by making eLearning modules available on demand.

About the Novartis Malaria Initiative The Novartis Malaria Initiative is committed to drive research, development and access to novel drugs to eliminate malaria. It is one of the pharmaceutical industry's largest access-to-medicine programs. Since 2001, the initiative has delivered more than 800 million treatments without profit, including over 300 million dispersible pediatric treatments, mostly to the public sector of malaria-endemic countries.

Novartis has a long heritage in antimalarial drug development. Coartem®, the first fixed-dose Artemisinin-based Combination Therapy (ACT), was launched in 1999. ACTs are the current standard of care in malaria treatment. Currently, Novartis leads two of the four most advanced malaria development programs worldwide, with two potential antimalarial therapies in Phase II clinical trials (KAF156 and KAE609). Both are new classes of compounds that treat malaria in different ways from current therapies, and could help combat growing resistance to existing artemisinin-based combination therapies.

The Novartis Malaria Initiative is integrated in Novartis Social Business, a unit which includes Novartis Access and the Novartis Healthy Family programs. This unit is operationally managed by Sandoz, the Novartis generics and biosimilars division.

DisclaimerThis press release contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as "to accelerate," "will," "confident," "continues to," "potential," "next-generation," "to further drive," "committed," "pipeline," "could," "would," or similar expressions. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such statements. These expectations could be affected by, among other things, risks and factors referred to in the Risk Factors section of Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update it in the future.

About NovartisNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com.